INDIGO

Development of novel influenza vaccine in the EU, India, and United States

Objective

To collaborate with partners in the EU, India and in the United States on the development of two novel influenza vaccine concepts that meet the requirements of global vaccination. We aim to have a sub 10% non-response rate, lower costs, and improve accessibility.


Description

INDIGO project involves public and private R&D organisations in the EU, India and United States for the development of two influenza vaccine concepts. The first concept combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel adjuvant, aiming to obtain proof-of-concept in phase I and II trials within 5 years. The second concept is based on innovations including a recombinant viral hemagglutinin with increased immunogenicity, a potent adjuvant and needle-free delivery by intradermal patches. The plans are realistic with a high probability to deliver next-generation flu vaccines.


Partners

Lite Vax

Univ Gent

Universitair Ziekenhuis Gent

ExpreS2ion Biotechnologies

Stanipharm

Cellvax

Viroclinics Biosciences BV

Institut National de la Sante et de la Recherche Medicale

EpiVax

Transnational Health Science And Technology Institute

CBCI Society for Medical Education

Council of Scientific and Industrial Research

Christian Medical College Vellore

Gennova Biopharmaceuticals Limited

Clinical Development Services Agency


Contact info

Sara Keller (s.keller@aighd.org)


Funders

European Commission Horizon 2020


Countries

Netherlands, Belgium, France, Denmark, India, United States